Pluristem Advances in MS Prevention
Pluristem Advances in MS Prevention
RedOrbit - Dallas,TX,USA
BrainStorm Cell Therapeutics Inc. of Petah Tikva, a leading developer of adult stem-cell technologies and therapeutics, announced last month that it has ...
See all stories on this topic
Helping his brother beat multiple sclerosis
Leader Post - Don Mills,ON,Canada
"Umbilical stem cells have the ability to regenerate my entire central nervous system with all-new myelin sheath and the umbilical fluid that protects the ...
See all stories on this topic
Forecast Insight: Multiple Sclerosis - Tysabri to prevail despite ...
Pharmaceutical Business Review - USA
Datamonitor remains highly positive on Novartis's FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline ...
See all stories on this topic
The Multidisciplinary Team in Multiple Sclerosis: Harnessing the ...
Medscape (subscription) - USA
Discussion of Off-Label, Investigational, or Experimental Drug Use: Cladribine, fingolimod, and teriflunamide. Disclosure: Dr. Turner: Sources of Funding ...
See all stories on this topic
Bulletin Board
West Haven News - Milford,CT,USA
There are more than 6000 Connecticut residents diagnosed with multiple sclerosis, an oftentimes debilitating disease affecting the central nervous system. ...
See all stories on this topic
Tysabri Forecast to Achieve Blockbuster Status by 2014
PharmiWeb.com (press release) - Bracknell,England,UK
18, 2008) - AVOS Life Sciences contends that Tysabri will exceed $1 billion in sales by 2014 as previously forecasted in the AVOS Therapeutic Market Outlook ...
See all stories on this topic
Medical condition shouldn't upset residents: Pisasale
Australian Broadcasting Corporation Sun, 17 Aug 2008 9:32 PM PDT
The Mayor of the Ipswich City Council - west of Brisbane - says he does not think residents will be upset that he did not tell them he had Multiple Sclerosis (MS).
She's on the run to help find a cure for MS
Miami Herald Tue, 19 Aug 2008 0:27 AM PDT
Eileen Friedman, 46 Plantation MS diagnosis: I was diagnosed with multiple sclerosis in 2000 after a head-on accident that totalled my car. I probably had MS 12 years prior because the symptoms came and went like a toothache. The pain in my head was intense, but I thought it was related to the accident. My brother has MS, so I went to see his neurologist
My Pharmiweb.com
PharmiWeb Tue, 19 Aug 2008 5:28 AM PDT
MORRISVILLE, N.C. (Aug. 18, 2008) - AVOS Life Sciences contends that Tysabri will exceed $1 billion in sales by 2014 as previously forecasted in the AVOS Therapeutic Market Outlook (TMO) Multiple Sclerosis Report released on July 1, 2008. In addition, the market dynamics featured in the report remain the same despite the recent cases of progressive multifocal leukoencephalopathy (PML) associated ...
furin Autoimmunity
Scientists find a novel mechanism that controls the development of ...
without furin only in T cells. What they discovered was that mice without furin in these cells developed. systemic autoimmune disease. ...
Figures and Tables : T-cell-expressed proprotein convertase furin ...
Development of age-related autoimmunity in CD4cre-furf/f mice. ... Furin deficiency results in increased T effector cell aggressiveness and impaired T ...
Older Adult Caregivers Of Dementia Sufferers Have Worse Sleep Than Noncaregivers
A study in the Journal of Clinical Sleep Medicine shows that the sleep patterns of older adults who live with and provide direct care during the night for a person with dementia are significantly worse than other older adults.
Immune Response May Hinder Stem Cell Treatments
Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate ...
MarketWatch - USA
Pipex is focused on developing products to treat, Dry Age-Related Macular Degeneration (AMD), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and ...
See all stories on this topic
Stem cells cloned from menstrual blood
Globe and Mail - Canada
Scientists around the world are working to harness the regenerative power of stem cells to repair the human body. Using embryonic stem cells is ...
See all stories on this topic
Clinical Trial Said to Have Been Marketing in Disguise
BELMONT, Mass. -- The ADVANTAGE trial comparing Merck’s rofecoxib (Vioxx) with naproxen (Aleve) was designed and executed primarily for marketing purposes, said researchers here. full story
http://www.medpagetoday.com/PublicHealthPolicy/ClinicalTrials/tb/10588
Top Stories
1. An old drug promises to slow aging process
2. Medco and FDA to study role of genetic tests
3. NIH creates new stem cell research center
4. CIRM offers $59M to inspire young scientists
5. Nanotubes superior at delivering chemotherapy
Also Noted: HESC study raises red flag; genetic link
Research News
Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London
Cannabis use in Spanish patients with multiple sclerosis: Fulfillment of patients' expectations?
In this cross-sectional study the authors investigated the use of cannabis in people with MS. They found that the use of cannabis for medicinal purposes was high among people with MS, although clinical improvement was reported by only half of them.
authors: Martínez-Rodríguez JE, Munteis E, Carreño M, Blanco Y, Roquer J, Abanades S, Graus F, Saiz A.
source: J Neurol Sci. 2008 Aug 6.
In multiple sclerosis, genes play a role and those related to the inflammatory response may be especially important. The authors of this study found that some specific genes involved in the immune response might be involved in the development of a second relapse of MS.
authors: Corvol JC, Pelletier D, Henry RG, Caillier SJ, Wang J, Pappas D, Casazza S, Okuda DT, Hauser SL, Oksenberg JR, Baranzini SE.
source: Proc Natl Acad Sci U S A. 2008 Aug 8
In MS, there is a certain level of change in the part of the brain that is not affected, to compensate for damage. The authors of this study have demonstrated that people with MS may have compensatory changes in the peripheral nervous system as well as the brain.
authors: Ng K, Howells J, Pollard JD, Burke D.
source: Brain. 2008 Aug 12
Will Rogers phenomenon in multiple sclerosis
Changes in the diagnostic criteria have allowed a diagnosis of MS in patients with a single relapse. The authors warn that these patients should not be grouped with patients diagnosed according to the old criteria in clinical trials, because they represent a different group with potentially different characteristics.
authors: Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, Filippi M, Montalban X.
source: Ann Neurol. 2008 Aug 7
The authors of this study found that in people with MS who respond well to interferon, there are specific changes in proteins involved in the immune response. They propose that these changes could be used as predictors of a good response to the drug.
authors: Carrieri PB, Ladogana P, Di Spigna G, Fulvia de Leva M, Petracca M, Montella S, Buonavolonta L, Florio C, Postiglione L.
source: Immunopharmacol Immunotoxicol. 2008 Aug 4:1-9.
MS News
Summaries of MS news from websites around the world.
US society-funded researchers find pattern of gene activity associated with high risk for MS
source: US National MS Society
In a major step towards discovering molecules that may be used as “markers” to predict MS disease activity and progression, researchers identified a pattern of gene expression within immune cells that was associated with quick conversion to MS in a study of 37 people with a first event suggestive of MS.
Canadian clinical trial research survey
source: University of Victoria, Canada
PhD students at the University of Victoria, Canada, are looking for people to take part in an online survey about how people search for clinical trials data.
Data centre chosen to foster research by US National MS Society Pediatric Centers of Excellence
source: US National MS Society
The network of Pediatric Centers of Excellence established by the US National MS Society has chosen the Collaborative Studies Coordinating Center at the University of North Carolina to coordinate and expedite its efforts to investigate MS in children.
Plaintiff-Paid Researchers: Merck Vioxx Study Was Marketing Ploy
A 1999 Merck & Co. study of its since-withdrawn painkiller Vioxx, touted to participating doctors and patients as meant to show whether Vioxx caused fewer stomach problems than another drug, was primarily a stealth marketing strategy, researchers report. The researchers who were working as paid consultants for lawyers representing plaintiffs who claimed Vioxx caused heart attacks or other harm, said they stumbled on documents indicating Merck's marketing division designed ADVANTAGE and handled the data collection and analysis.
Vioxx study more about marketing than science, says report
The suspected practice of passing marketing studies off as scientific research has come under the microscope following a report which points the finger at Merck & Co and a 1999 study of its COX-2 inhibitor Vioxx
read more
Pharma industry rejects NICE chief's profiteering claims
The chief of the UK’s drug cost-effectiveness watchdog has torn a strip off the pharmaceutical industry saying that the latter’s desire for higher profits are driving up prices, a claim drugmakers have been quick to deny
read more
Cholesterol Drug Plays Role in Melanoma Remission
From PR Newswire - Aug 12, 2008
NASHVILLE, Tenn., August 12, 2008 /PRNewswire/ -- A drug widely used to treat high cholesterol is helping beat cancer. Lovastatin is part of a new cancer treatment that has arrested or eradicated tumors in more than 80% of initial patients.
Read Full Article Article Summary
posted by Bill at 4:20 PM
0 Comments:
Post a Comment
<< Home